Designer natriuretic peptides, including CD-NP, ANX-042, and MANP, demonstrate enhanced receptor activation and resistance to enzymatic degradation in early clinical trials for heart failure and hypertension.
Endogenous natriuretic peptides serve as potent activators of particulate guanylyl cyclase receptors and the second messenger cGMP. Natriuretic peptides are essential in maintenance of volume homeostasis, and can be of myocardial, renal and endothelial origin. Advances in peptide engineering have permitted the ability to pursue highly innovative drug discovery strategies. This has resulted in designer natriuretic peptides that go beyond native peptides in efficacy, specificity, and resistance to enzymatic degradation. Together with recent improvements in peptide delivery systems, which have improved bioavailability, further advances in this field have been made. Therefore, designer natriuretic peptides with pleotropic actions together with strategies of chronic delivery have provided an unparalleled opportunity for the treatment of cardiovascular disease. In this review, we report the conceptual framework of peptide engineering of the natriuretic peptides that resulted in designer peptides for cardiovascular disease. We specifically provide an update on those currently in clinical trials for heart failure and hypertension, which include Cenderitide, ANX042 and ZD100.
Meems et al. (Thu,) conducted a review in Heart failure and hypertension. Designer Natriuretic Peptides was evaluated. Designer natriuretic peptides, including CD-NP, ANX-042, and MANP, demonstrate enhanced receptor activation and resistance to enzymatic degradation in early clinical trials for heart failure and hypertension.